Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.
Actively Recruiting
Ulcerative colitis UC is an inflammatory bowel disease causing inflammation and bleeding in the rectum and colon. This study evaluates the change in disease activity in adult participants with moderate to severe UC who are treated with risankizumab in real-world clinical practice. The study is observational and will include about 200 participants across multiple sites in Germany and Austria. Participants will receive risankizumab as prescribed by their physicians according to routine clinical care and local guidelines. The treatment is not assigned by the study team but follows the physicians decision. Participants will be observed and followed for up to 52 weeks while receiving this treatment under normal clinical conditions. During the study, participants will attend regular visits at hospitals or clinics as part of their routine care. There will be no additional burden beyond regular clinical visits. Researchers will measure the percentage of participants achieving symptomatic remission based on the Partial Adapted Mayo Score over approximately 52 weeks. Safety and effectiveness of risankizumab will be monitored throughout the study period.